Actionable news
All posts from Actionable news
Actionable news in EGLT: EGALET CORPORATION,

Egalet Reports Q3 Results, Offers ARYMO ER Updates

  • Revenue of $4.7 million beat by $0.1 million.
  • Company highlighted FDA Advisory Committee's recommended approval of ARYMO ER during the quarter.
  • Company also highlighted closing of $40 million in financing during the quarter.
  • Cash and marketable securities totaled $101.2 million at the end of the quarter.
  • CEO Bob Radie expects the FDA to finalize review of ARYMO ER in time for a potential launch in the first quarter of 2017.

© 2016 Benzinga does not provide investment advice. All rights reserved.